Renovare Therapeutics Emerges from Stealth Mode with $33.5M ARPA-H Funding for Osteoarthritis Regenerative Therapies
Key Insights
Renovare Therapeutics (search) launched from stealth mode in April 2026, collaborating with University of Colorado Boulder on a $33.5 million ARPA-H (search) contract to develop regenerative osteoarthritis therapies.
The company's platform technologies include controlled drug delivery systems, novel gene therapies, and advanced regenerative biomaterials designed to halt and reverse osteoarthritis disease progression.
Lead product candidates are advancing toward IND-enabling studies in 2026, targeting the more than 32 million Americans affected by osteoarthritis with potentially transformative regenerative treatments.
Renovare Therapeutics (search), a privately-held biotechnology company, announced its formal launch from stealth mode in April 2026, marking a significant milestone in the development of regenerative therapies for osteoarthritis. The company emerged through a collaboration with University of Colorado Boulder, which secured a contract of up to $33.5 million from the Advanced Research Projects Agency for Health (ARPA-H (search)) under the Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program.
The non-dilutive funding will support the continued development of lead product candidates through IND-enabling studies and first-in-human Phase 1 safety trials. The ARPA-H (search) NITRO program, led by Program Manager Dr. Ross Uhrich, is specifically designed to accelerate breakthrough therapies that restore joint function and quality of life for the more than 32 million Americans affected by osteoarthritis.
Platform Technology and Pipeline Development
Renovare's platform is built on core technological innovations developed at CU Boulder, CU Anschutz, and Colorado State University. The company's technologies encompass three key areas: controlled drug delivery systems, novel gene therapies administered via intra-articular injection or intravenous infusion, and advanced regenerative biomaterials for cartilage and bone lesion treatment delivered arthroscopically.
The multi-institutional research team, which includes scientists from CU Boulder, CU Anschutz, and Colorado State University, has completed nonclinical research and development on several unique products over the past two years. These product candidates represent novel approaches to treat osteoarthritis, a degenerative joint disease that results in loss of cartilage and bone tissue, causing debilitating pain, loss of mobility, and reduced quality of life.
Unlike current treatments that largely provide only symptomatic relief, Renovare's innovative products aim to be regenerative, potentially halting and reversing disease progression and enabling patients to reclaim active lifestyles. The company's pipeline includes products that can be customized or combined to treat osteoarthritis patients at any stage of disease, with lead assets advancing towards IND-enabling studies in 2026.
Leadership and Scientific Expertise
The company's management team brings extensive biotechnology experience to the osteoarthritis space. Chief Executive Officer Liz Scott has over twenty years of experience in business executive roles at established and emerging biotech companies, including Genentech, Array Biopharma (acquired by Pfizer), and Reata Pharmaceuticals (acquired by Biogen). Scott has guided more than nine new products through clinical development, regulatory approvals, and rapid commercial adoption, culminating in over $18 billion in acquisitions and numerous blockbuster launches.
Dr. Stephanie Bryant serves as Chief Scientific Officer and founder of Renovare, leading the scientific vision as the principal investigator on the ARPA-H (search) NITRO award. Bryant holds the position of Provost Endowed Professor of Chemical and Biological Engineering, Director of the Materials Science and Engineering Program, and member of BioFrontiers Institute at the University of Colorado Boulder. Her twenty-five plus years of research on Renovare's core technologies have yielded authorship of over 145 publications and fifteen U.S. patents issued or pending.
"This award is a significant milestone for our team, for Renovare, and for the future of osteoarthritis care," said Dr. Bryant. "We are grateful for ARPA-H (search)'s partnership and confidence in our team's vision to create therapies that are designed to address the unmet needs of osteoarthritis patients. After spending my academic career developing these technologies, it is thrilling to see them advance toward the clinic where their potential to make a difference in the lives of patients is inspiring."
Dr. Karin Payne, Chief Development Officer, serves as Co-PI on the ARPA-H (search) NITRO award and Associate Professor of Orthopedics and Director of Education for the Colorado Program for Musculoskeletal Research at the University of Colorado Anschutz. Her decades of research and innovations in cartilage and bone regeneration have been integral to Renovare's preclinical programs.
Scientific Advisory Board
The company's Scientific Advisory Board includes recognized experts in osteoarthritis, gene therapy, and cartilage and bone regeneration. Dr. Laurie Goodrich, a board-certified large animal surgeon and Professor of Orthopedics at Colorado State University's College of Veterinary Medicine & Biomedical Sciences, serves as Director of the Orthopaedic Research Center and holds the Barbara Cox University Chair in Orthopaedics.
Dr. Kelly Santangelo, a board-certified veterinary pathologist and Professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, focuses on the pathogenesis of musculoskeletal conditions in translational animal models. Dr. Mike Zuscik, the Mack Clayton Professor of Orthopedics and Vice Chair of Research at the University of Colorado Anschutz Medical Campus, brings nationally recognized leadership in musculoskeletal biology and joint degeneration mechanisms.
Commercial Vision and Future Applications
"Support from the NITRO program will accelerate our translational pipeline development and empower us to advance potentially transformative solutions for a long-overlooked disease area," said CEO Liz Scott. "With Renovare's technologies having broad applicability beyond osteoarthritis, we are excited to build a biotechnology company of significant value to patients, providers, and community stakeholders."
The company's mission extends beyond osteoarthritis to address other conditions with significant unmet medical needs. Headquartered in Boulder, Colorado, Renovare aims to advance regenerative therapies that restore function and transform care for patients with musculoskeletal diseases, leveraging its platform technologies with broad potential applications across multiple therapeutic areas.